Emerging Drugs and Formulations for Pain Treatment

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 10 October 2025 | Viewed by 863

Special Issue Editors


E-Mail Website
Guest Editor
Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Col. Casco de Santo Tomas, Miguel Hidalgo, Mexico City 11340, Mexico
Interests: obesity; pain; experimental pain treatment; physiopathology of pain; experimental therapeutics

E-Mail Website
Guest Editor
Centro de Investigación y Docencia en Ciencias de la Salud, Universidad Autónoma de Sinaloa, Eustaquio Buelna 91, Burócrata, Culiacan 80030, Mexico
Interests: pain; neuropathy; neuropharmacology; pain treatment; opioid drugs; cannabinoid-based medicine

Special Issue Information

Dear Colleagues,

The global burden of pain has increased in recent times, and although measuring pain is complicated, approximately 20% of the population suffers from pain of a chronic nature. In this regard, it is important to recognize that chronic pain damages the quality of life of patients, and in the same way, it results in a higher cost to private and public health systems. Although analgesic marketed drugs produce a significant release from pain, a considerable number of patients do not experience pain relief. Also, the side effects of these conventional drugs lead to the abandonment of pharmacological management of pain. Relief from pain is a human right; however, the existence of significant barriers such as the lack of individualized therapies, the increased opioid crisis, and the undertreated patients with difficult pain syndromes can make this process difficult. In response to overcoming the major barriers of pharmacological pain treatment, we are pleased to invite all researchers of preclinical and clinical areas to contribute to this Special Issue entitled “Emerging Drugs and Formulations for Pain Treatment”. Original and review articles on preclinical and clinical findings focused on new drug design, reformulations, combined therapies, drug targeting, nanomedicine, delivery and controlled-release systems for drugs, advanced pharmacogenomics and pharmacogenetics therapies, and improved pharmacokinetic and pharmacodynamics processes of analgesic drugs, which enhance the understanding of treatment and release of pain, are welcome. Research areas include (but are not limited to) chronic, neuropathic, nociplastic, oncologic, and rare syndromes of pain conditions and others.

We look forward to receiving your contributions.

Dr. Hector Isaac Rocha-González
Dr. Geovanna Nallely Quiñonez-Bastidas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • analgesia
  • experimental pain treatment
  • preclinical models
  • pharmacotherapeutic management of pain
  • new drugs in clinical trials
  • drug development
  • psychotropic drugs
  • natural compounds
  • neuropathic Pain
  • chronic pain
  • synthetic drugs
  • new formulations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2931 KiB  
Article
Evaluation of the Antinociceptive Effect of Sesamin: Role of 5HT1A Serotonergic Receptors
by Roberto Camacho-Cruz, David Francisco Alcalá-Hernández, Juan Carlos Huerta-Cruz, Jesús Arrieta-Valencia, María Elena Sánchez-Mendoza, Francisco Javier Flores-Murrieta, Andrés Navarrete, Juan Gerardo Reyes-García and Héctor Isaac Rocha-González
Pharmaceutics 2025, 17(3), 330; https://doi.org/10.3390/pharmaceutics17030330 - 3 Mar 2025
Viewed by 607
Abstract
Background/Objectives: Sesame (Sesamum indicum L.) is used in folk medicine to treat painful disorders. Sesamin is the main lignan found in this plant; however, its antinociceptive potential has scarcely been studied. The aim was to investigate the antinociceptive effect of sesamin on [...] Read more.
Background/Objectives: Sesame (Sesamum indicum L.) is used in folk medicine to treat painful disorders. Sesamin is the main lignan found in this plant; however, its antinociceptive potential has scarcely been studied. The aim was to investigate the antinociceptive effect of sesamin on inflammatory and neuropathic pain models, as well as the possible mechanism of action through which sesamin mediates its own antinociceptive effect. Methods: Formalin and carrageenan animal models were used to assess inflammatory pain, whereas an L5/L6-spinal-nerve-ligated rat model was employed to evaluate neuropathic pain. Results: Oral sesamin significantly reduced carrageenan-induced hyperalgesia and inflammation, formalin-induced nociception, and L5/L6-spinal-nerve-ligation-induced allodynia. Sesamin was more effective than diclofenac in the inflammatory pain models, but it was less effective than pregabalin in the neuropathic pain model. The antinociceptive effect of sesamin, in the formalin test, was prevented by the intraperitoneal administration of methiothepin (5-HT1/5 antagonist), but not by naltrexone (an opioid antagonist) or L-NAME (an NOS inhibitor). In addition, WAY-100635 (5-HT1A antagonist), but not SB-224289 (5-HT1B antagonist), BRL-15542 (5-HT1D antagonist), and SB-699551 (5-HT5A antagonist), impeded sesamin-induced antinociception. Conclusions: This study’s results support the use of sesamin to treat inflammatory pain disorders and suggest that 5-HT1A receptors influence the antinociceptive effect of this drug. Full article
(This article belongs to the Special Issue Emerging Drugs and Formulations for Pain Treatment)
Show Figures

Figure 1

Back to TopTop